-transparent.png){kind=logo}
The present study characterized the serotonin (5-HT) receptor subtypes mediating adrenal corticotropic hormone (ACTH) and corticosterone responses to 5-HT agonists in conscious rats. The 5-HT2A/5-HT2C agonist (+/-(-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HC1 (DOI) increased plasma ACTH and corticosterone in a dose-dependent manner. The 5-HT2A/5-HT2C antagonist ritanserin (0.01 and 0.1 mg/kg sc) inhibited the DOI-induced increase in plasma ACTH, but not corticosterone. Low doses of spiperone (0.01 and 0.1 mg/kg sc) significantly reduced the ACTH response to DOI. Because spiperone has a higher affinity for 5-HT2A than 5-HT2C receptors, these data suggest that DOI stimulates ACTH secretion through 5-HT2A receptors. 5-methoxy-3-[1,2,3,4-tetrahydro-4-pyridinyl]-1H-indole (RU 24969) is a potent 5-HT1A/1B and moderate 5-HT2C agonist that also has been suggested to release 5-HT. However, p-chlorophenylalanine (PCPA) did not reduce the effect of RU 24969 on plasma ACTH, suggesting that RU 24969 only acts as a direct agonist. 6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid (LY53857) injected into the lateral cerebral ventricles (i.c.v.) inhibited the ACTH, but not corticosterone response to peripheral injection of RU 24969, suggesting that central 5-HT2A/2C receptors mediate the ACTH response. LY53857 injection (i.c.v.) also inhibited the effect of p-chloroamphetamine (i.c.v.) on plasma ACTH. However, the corticosterone response was not inhibited by LY53857, suggesting a distinct location of 5-HT receptors regulating corticosterone secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
September 2016,
Neuropharmacology,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
October 2014,
Neuroscience letters,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
February 2009,
Pharmacology & therapeutics,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
January 2016,
Frontiers in pharmacology,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
August 2004,
The Journal of pharmacology and experimental therapeutics,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
April 1984,
Federation proceedings,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
January 1996,
Behavioural brain research,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
December 1995,
Pharmacology, biochemistry, and behavior,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
February 2020,
ACS omega,
P A Rittenhouse, and
E A Bakkum, and
A D Levy, and
Q Li, and
M Carnes, and
L D van de Kar
June 1996,
European journal of pharmacology,
